Amgen balance sheet

At the end of fiscal 2025, Amgen had total assets of $90.59bn and shareholders' equity of $8.66bn. It held $9.13bn in cash against $54.60bn of debt: net debt of $45.48bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Amgen: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	2.9	3.3	6.9	3.3	3.8	3.7	4.1	3.2	3.8	6.9	6.0	6.3	8.0	7.6	10.9	12.0	9.1	14.0
Receivables	2.1	2.3	2.9	2.5	2.7	2.5	3.0	3.2	3.2	3.6	4.1	4.5	4.9	5.6	7.3	6.8	9.6	10.2
Inventory	2.2	2.0	2.5	2.7	3.0	2.6	2.4	2.7	2.8	2.9	3.6	3.9	4.1	4.9	9.5	7.0	6.2	6.2
Total current assets	18.9	23.1	27.6	31.2	27.4	34.7	38.5	46.0	49.5	37.6	18.4	21.1	19.4	22.2	30.3	29.0	29.1	35.0
Goodwill	11.3	11.3	11.8	12.7	15.0	14.8	14.8	14.8	14.8	14.7	14.7	14.7	14.9	15.5	18.6	18.6	18.7	18.7
Total assets	39.6	43.5	48.9	54.3	66.1	69.0	71.4	77.6	80.0	66.4	59.7	62.9	61.2	65.1	97.2	91.8	90.6	95.6
Accounts payable	0.6	0.7	0.6	0.9	0.8	1.0	1.0	0.9	1.4	1.2	1.4	1.4	1.4	1.6	1.6	1.9	2.4	2.9
Total current liabilities	3.9	6.6	5.8	8.2	7.9	7.0	8.7	11.2	9.0	13.5	12.8	11.7	12.2	15.7	18.4	23.1	25.5	25.5
Short-term debt	—	—	—	—	2.5	0.5	2.2	4.4	1.2	4.4	3.0	0.1	0.1	1.6	1.4	3.6	4.6	5.4
Long-term debt	10.6	10.9	21.4	26.5	29.6	30.2	29.2	30.2	34.2	29.5	27.0	32.9	33.2	37.4	63.2	56.5	50.0	51.9
Total debt	10.6	15.9	21.5	29.0	34.6	30.7	31.4	34.6	35.3	33.9	29.9	33.0	33.3	38.9	64.6	60.1	54.6	57.3
Shareholders' equity	22.7	23.9	19.0	19.1	22.1	25.8	28.1	29.9	25.2	12.5	9.7	9.4	6.7	3.7	6.2	5.9	8.7	11.7
Net debt (negative = net cash)	7.7	12.6	14.6	25.8	30.8	27.0	27.3	31.4	31.5	27.0	23.9	26.7	25.3	31.3	53.7	48.1	45.5	43.3
Shares outstanding	995m	932m	796m	756m	755m	760m	754m	738m	722m	630m	591m	578m	558m	534m	535m	537m	539m	541m

US$ billions unless shown otherwise. Fiscal quarters.

Amgen: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	7.3	6.8	8.1	8.7	8.5	9.6	9.1	10.2
Inventory	7.4	7.0	6.7	6.6	6.3	6.2	6.2	6.2
Total current assets	26.8	29.0	26.9	26.7	27.9	29.1	31.5	35.0
Goodwill	18.7	18.6	18.6	18.7	18.7	18.7	18.7	18.7
Total assets	90.9	91.8	89.4	87.9	90.1	90.6	92.5	95.6
Accounts payable	2.1	1.9	2.4	3.0	2.8	2.4	2.9	2.9
Total current liabilities	20.3	23.1	23.0	20.5	21.8	25.5	25.0	25.5
Short-term debt	3.5	3.6	3.4	2.4	2.2	4.6	5.4	5.4
Long-term debt	56.9	56.5	54.0	53.8	52.4	50.0	51.9	51.9
Total debt	60.4	60.1	57.4	56.2	54.6	54.6	57.3	57.3
Shareholders' equity	7.5	5.9	6.2	7.4	9.6	8.7	9.2	11.7
Shares outstanding	538m	537m	538m	538m	539m	539m	540m	541m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AMGN vs GILD ABBV vs AMGN AMGN vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Amgen's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amgen.